Analysis of effectiveness and safety of sodium glycididazole on radiotherapy for esophagus cancer
10.13699/j.cnki.1001-6821.2018.03.054
- VernacularTitle:甘氨双唑钠对食管癌放疗增敏作用疗效与安全性的分析
- Author:
Zhen-Zhen YANG
1
;
Kai WANG
;
Sheng HAN
;
Zhi-Qing ZHANG
Author Information
1. 河北医科大学第二医院药学部
- Keywords:
esophagus cancer;
glycididazolum natrium;
sodium glycididazole;
radiotherapy;
Meta-analysis
- From:
The Chinese Journal of Clinical Pharmacology
2018;34(3):365-368
- CountryChina
- Language:Chinese
-
Abstract:
Objective To systematically evaluate the effectiveness and safety of sodium glycididazole (CMNa) combined with radiotherapy in the treatment of esophagus cancer.Methods Databases including China National Knowledge Infrastructure,Wanfang Database,VIP and MedLine (PubMed) database were searched,and the date of publication was up to May 2017.Randomized controlled trials of CMNa combined with radiotherapy (treatment group) and radiotherapy alone (control group) in the treatment of esophagus cancer were retrieved from these datebases.Complete response rate、effective rate、survival rate and adverse drug reactions were performed by using Rev Man 5.3 statistical software.Results A total of 13 articles were included,involving 1073 patients.Effective rates of treatment and control groups were 92.71％ (496 cases/535 cases) and 77.32％ (416 cases/538 cases),complete response rates of treatment and control groups were 43.55％ (233 cases/535 cases) and 25.28％ (136 cases/538 cases),one year survival rate of treatment and control groups were 78.92％ (131 case/166case) and 53.76％ (93 case/173 case),all discrepancies had statistical differences (P ＜ 0.001,P ＜ 0.01).There were no serious adverse drug reactions in both groups.Total incidences of adverse drug reactions in treatment and control groups were 41.94％ (78 cases/186 cases) and 43.00％ (83 cases/193 cases) without statistically difference (P ＞0.05).Conclusion CMNa on radiotherapy for esophagus cancer is rehable in the short term,with a good safety.But the long-term effects need to be further studied in clinical trials.
